News

  • Tools to encourage the development of integrated thinking

    Given the pace of innovation in drug development, a major challenge for Clinical Pharmacology in biotech and pharma is how it maintains relevance as a key integrator and applier of knowledge to accelerate the development of medicines.

    Keith Nieforth
  • We are all in this together! Paths to better collaboration for drug discovery and development

    Patrick Smith and Craig Rayner will be presenting the keynote address at the ASCEPT 2013 Annual Scientific Meeting, in Melbourne Australia.

    Patrick Smith
  • Cenicriviroc PK/PD Analyses Presented at European AIDS Conference

    d3 medicine contributed to exposure-response analyses and rationale to support Cenicriviroc (Tobira Therapeutics) dose selection for Phase 3. The results of the PK/PD investigations will be presented by the Tobira team at the European AIDS Conference.

    Patrick Smith
  • Wall Street Journal: Arch Biopartners Appoints Patrick Smith and Craig Rayner as Drug Development Advisors

    Arch Biopartners Appoints Patrick Smith and Craig Rayner as Drug Development Advisors. In this capacity, Dr. Smith and Dr.

    d3
  • New Publications: Clinical Implications of Hepatitis C Protease Inhibitor Drug Interactions

    d3 medicine Investigators have recently published 4 manuscripts which lend important new insights into the emerging and challenging area of HCV small molecule therapeutics, where drug-drug interactions are of significant concern.

    Patrick Smith
  • New Publications: Clinical pharmacology insights into Oseltamivir

    Two publications on oseltamivir clinical PK/PD have been published ahead of print in  Antimicrobial Agents and Chemotherapy.

    Craig Rayner
  • BioMelbourne Network BioBriefing: Driving Global Best Practice in Drug Development in Victoria: Malaria Case Study

    Dr. Craig Rayner will chair a BioMelbourne Network Biobriefing: Driving Global Best Practice in Drug Development in Victoria:Malaria Case Study.

    Craig Rayner

Pages